Vertex Pharmaceuticals Inc. said it secured a $500 million senior unsecured revolving facility from lenders led by Bank of America NA.
The credit line expires Sept. 17, 2024, and replaces an existing credit agreement. The Boston-based biopharmaceutical company may request an additional $500 million extension to the credit facility.
Amounts borrowed under the facility will bear interest at the company's option at either a base rate or a Eurocurrency rate plus an applicable margin.
